Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study.
Identifieur interne : 000082 ( Main/Corpus ); précédent : 000081; suivant : 000083Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study.
Auteurs : Jakob P. Cramer ; Katrin Dubischar ; Susanne Eder ; Gerd D. Burchard ; Tomas Jelinek ; Bernd Jilma ; Herwig Kollaritsch ; Emil Reisinger ; Kerstin WestritschnigSource :
- Vaccine [ 1873-2518 ] ; 2016.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Antibodies, Viral (blood), Austria, Encephalitis, Japanese (prevention & control), Female, Germany, Humans, Immunization, Secondary, Immunogenicity, Vaccine, Japanese Encephalitis Vaccines (adverse effects), Japanese Encephalitis Vaccines (immunology), Japanese Encephalitis Vaccines (therapeutic use), Male, Prospective Studies, Seroconversion.
- MESH :
- chemical , adverse effects : Japanese Encephalitis Vaccines.
- chemical , blood : Antibodies, Viral.
- chemical , immunology : Japanese Encephalitis Vaccines.
- prevention & control : Encephalitis, Japanese.
- chemical , therapeutic use : Japanese Encephalitis Vaccines.
- Aged, Aged, 80 and over, Austria, Female, Germany, Humans, Immunization, Secondary, Immunogenicity, Vaccine, Male, Prospective Studies, Seroconversion.
Abstract
BACKGROUND
IXIARO® is a Vero cell-derived, inactivated Japanese encephalitis (JE) vaccine licensed mainly in western countries for children and adults traveling to JE endemic areas. Limited immunogenicity and safety data in elderly travelers have been available.
OBJECTIVES
To evaluate safety and immunogenicity of IXIARO in elderly subjects.
METHODS
Open-label, single arm, multi-centered study. Two-hundred subjects with good general health, including adequately controlled chronic conditions, received two doses of IXIARO®, 28days apart. Protective levels of antibodies were tested 42days after the second dose. Systemic and local adverse events (AEs) were solicited for 7days after each dose, unsolicited AEs were collected up to day 70 and in a phone call at month 7.
SUMMARY OF RESULTS
Subjects were aged 64-83years (median 69.0years). Nineteen percent of subjects had serious or medically attended AEs up to Day 70 (primary endpoint), none of them causally linked to IXIARO. Solicited local AEs were reported by 33.5% (most common: local tenderness) and solicited systemic AEs by 27% (most common: headache) of subjects. The seroprotection rate was 65% with a geometric mean titre (GMT) of 37. Subjects with tick borne encephalitis (TBE) vaccinations in the past 5years (N=29) had a SCR of 90% and GMT of 65.
CONCLUSIONS
IXIARO is generally well tolerated in the elderly, and the safety profile is largely comparable with younger adults. SCR and GMT are lower compared to younger adults, but SCR is in the range reported in elderly for other vaccines e.g. against TBE, hepatitis-A virus (HAV)/hepatitis-B virus (HBV), influenza. The differences in SCR and GMT from younger to elderly adults were in the range of other vaccines. Duration of protection is uncertain in older persons, therefore a booster dose (third dose) should be considered before any further exposure to JE virus.
DOI: 10.1016/j.vaccine.2016.07.029
PubMed: 27460550
Links to Exploration step
pubmed:27460550Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study.</title><author><name sortKey="Cramer, Jakob P" sort="Cramer, Jakob P" uniqKey="Cramer J" first="Jakob P" last="Cramer">Jakob P. Cramer</name><affiliation><nlm:affiliation>Bernhard Nocht Centre for Clinical Trials, Section Tropical Medicine/Infectious Diseases, I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany(1); Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Dubischar, Katrin" sort="Dubischar, Katrin" uniqKey="Dubischar K" first="Katrin" last="Dubischar">Katrin Dubischar</name><affiliation><nlm:affiliation>Valneva Austria GmbH, Campus Vienna Biocenter 3, 1030 Vienna, Austria. Electronic address: Katrin.dubischar@valneva.com.</nlm:affiliation></affiliation></author><author><name sortKey="Eder, Susanne" sort="Eder, Susanne" uniqKey="Eder S" first="Susanne" last="Eder">Susanne Eder</name><affiliation><nlm:affiliation>Valneva Austria GmbH, Campus Vienna Biocenter 3, 1030 Vienna, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Burchard, Gerd D" sort="Burchard, Gerd D" uniqKey="Burchard G" first="Gerd D" last="Burchard">Gerd D. Burchard</name><affiliation><nlm:affiliation>Bernhard Nocht Centre for Clinical Trials, Section Tropical Medicine/Infectious Diseases, I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany(1); Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Jelinek, Tomas" sort="Jelinek, Tomas" uniqKey="Jelinek T" first="Tomas" last="Jelinek">Tomas Jelinek</name><affiliation><nlm:affiliation>Berlin Center for Travel & Tropical Medicine, Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Jilma, Bernd" sort="Jilma, Bernd" uniqKey="Jilma B" first="Bernd" last="Jilma">Bernd Jilma</name><affiliation><nlm:affiliation>Department of Clinical Pharmacology, Medical University of Vienna, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Kollaritsch, Herwig" sort="Kollaritsch, Herwig" uniqKey="Kollaritsch H" first="Herwig" last="Kollaritsch">Herwig Kollaritsch</name><affiliation><nlm:affiliation>Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Reisinger, Emil" sort="Reisinger, Emil" uniqKey="Reisinger E" first="Emil" last="Reisinger">Emil Reisinger</name><affiliation><nlm:affiliation>Department of Tropical Medicine & Infectious Diseases, Rostock University Medical Center, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Westritschnig, Kerstin" sort="Westritschnig, Kerstin" uniqKey="Westritschnig K" first="Kerstin" last="Westritschnig">Kerstin Westritschnig</name><affiliation><nlm:affiliation>Valneva Austria GmbH, Campus Vienna Biocenter 3, 1030 Vienna, Austria.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27460550</idno><idno type="pmid">27460550</idno><idno type="doi">10.1016/j.vaccine.2016.07.029</idno><idno type="wicri:Area/Main/Corpus">000082</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000082</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study.</title><author><name sortKey="Cramer, Jakob P" sort="Cramer, Jakob P" uniqKey="Cramer J" first="Jakob P" last="Cramer">Jakob P. Cramer</name><affiliation><nlm:affiliation>Bernhard Nocht Centre for Clinical Trials, Section Tropical Medicine/Infectious Diseases, I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany(1); Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Dubischar, Katrin" sort="Dubischar, Katrin" uniqKey="Dubischar K" first="Katrin" last="Dubischar">Katrin Dubischar</name><affiliation><nlm:affiliation>Valneva Austria GmbH, Campus Vienna Biocenter 3, 1030 Vienna, Austria. Electronic address: Katrin.dubischar@valneva.com.</nlm:affiliation></affiliation></author><author><name sortKey="Eder, Susanne" sort="Eder, Susanne" uniqKey="Eder S" first="Susanne" last="Eder">Susanne Eder</name><affiliation><nlm:affiliation>Valneva Austria GmbH, Campus Vienna Biocenter 3, 1030 Vienna, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Burchard, Gerd D" sort="Burchard, Gerd D" uniqKey="Burchard G" first="Gerd D" last="Burchard">Gerd D. Burchard</name><affiliation><nlm:affiliation>Bernhard Nocht Centre for Clinical Trials, Section Tropical Medicine/Infectious Diseases, I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany(1); Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Jelinek, Tomas" sort="Jelinek, Tomas" uniqKey="Jelinek T" first="Tomas" last="Jelinek">Tomas Jelinek</name><affiliation><nlm:affiliation>Berlin Center for Travel & Tropical Medicine, Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Jilma, Bernd" sort="Jilma, Bernd" uniqKey="Jilma B" first="Bernd" last="Jilma">Bernd Jilma</name><affiliation><nlm:affiliation>Department of Clinical Pharmacology, Medical University of Vienna, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Kollaritsch, Herwig" sort="Kollaritsch, Herwig" uniqKey="Kollaritsch H" first="Herwig" last="Kollaritsch">Herwig Kollaritsch</name><affiliation><nlm:affiliation>Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Reisinger, Emil" sort="Reisinger, Emil" uniqKey="Reisinger E" first="Emil" last="Reisinger">Emil Reisinger</name><affiliation><nlm:affiliation>Department of Tropical Medicine & Infectious Diseases, Rostock University Medical Center, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Westritschnig, Kerstin" sort="Westritschnig, Kerstin" uniqKey="Westritschnig K" first="Kerstin" last="Westritschnig">Kerstin Westritschnig</name><affiliation><nlm:affiliation>Valneva Austria GmbH, Campus Vienna Biocenter 3, 1030 Vienna, Austria.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Antibodies, Viral (blood)</term><term>Austria</term><term>Encephalitis, Japanese (prevention & control)</term><term>Female</term><term>Germany</term><term>Humans</term><term>Immunization, Secondary</term><term>Immunogenicity, Vaccine</term><term>Japanese Encephalitis Vaccines (adverse effects)</term><term>Japanese Encephalitis Vaccines (immunology)</term><term>Japanese Encephalitis Vaccines (therapeutic use)</term><term>Male</term><term>Prospective Studies</term><term>Seroconversion</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Japanese Encephalitis Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Japanese Encephalitis Vaccines</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Encephalitis, Japanese</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Japanese Encephalitis Vaccines</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Austria</term><term>Female</term><term>Germany</term><term>Humans</term><term>Immunization, Secondary</term><term>Immunogenicity, Vaccine</term><term>Male</term><term>Prospective Studies</term><term>Seroconversion</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>IXIARO® is a Vero cell-derived, inactivated Japanese encephalitis (JE) vaccine licensed mainly in western countries for children and adults traveling to JE endemic areas. Limited immunogenicity and safety data in elderly travelers have been available.</p></div><div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b></p><p>To evaluate safety and immunogenicity of IXIARO in elderly subjects.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Open-label, single arm, multi-centered study. Two-hundred subjects with good general health, including adequately controlled chronic conditions, received two doses of IXIARO®, 28days apart. Protective levels of antibodies were tested 42days after the second dose. Systemic and local adverse events (AEs) were solicited for 7days after each dose, unsolicited AEs were collected up to day 70 and in a phone call at month 7.</p></div><div type="abstract" xml:lang="en"><p><b>SUMMARY OF RESULTS</b></p><p>Subjects were aged 64-83years (median 69.0years). Nineteen percent of subjects had serious or medically attended AEs up to Day 70 (primary endpoint), none of them causally linked to IXIARO. Solicited local AEs were reported by 33.5% (most common: local tenderness) and solicited systemic AEs by 27% (most common: headache) of subjects. The seroprotection rate was 65% with a geometric mean titre (GMT) of 37. Subjects with tick borne encephalitis (TBE) vaccinations in the past 5years (N=29) had a SCR of 90% and GMT of 65.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>IXIARO is generally well tolerated in the elderly, and the safety profile is largely comparable with younger adults. SCR and GMT are lower compared to younger adults, but SCR is in the range reported in elderly for other vaccines e.g. against TBE, hepatitis-A virus (HAV)/hepatitis-B virus (HBV), influenza. The differences in SCR and GMT from younger to elderly adults were in the range of other vaccines. Duration of protection is uncertain in older persons, therefore a booster dose (third dose) should be considered before any further exposure to JE virus.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27460550</PMID><DateCompleted><Year>2017</Year><Month>11</Month><Day>13</Day></DateCompleted><DateRevised><Year>2017</Year><Month>12</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>38</Issue><PubDate><Year>2016</Year><Month>08</Month><Day>31</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study.</ArticleTitle><Pagination><MedlinePgn>4579-4585</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(16)30612-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2016.07.029</ELocationID><Abstract><AbstractText Label="BACKGROUND">IXIARO® is a Vero cell-derived, inactivated Japanese encephalitis (JE) vaccine licensed mainly in western countries for children and adults traveling to JE endemic areas. Limited immunogenicity and safety data in elderly travelers have been available.</AbstractText><AbstractText Label="OBJECTIVES">To evaluate safety and immunogenicity of IXIARO in elderly subjects.</AbstractText><AbstractText Label="METHODS">Open-label, single arm, multi-centered study. Two-hundred subjects with good general health, including adequately controlled chronic conditions, received two doses of IXIARO®, 28days apart. Protective levels of antibodies were tested 42days after the second dose. Systemic and local adverse events (AEs) were solicited for 7days after each dose, unsolicited AEs were collected up to day 70 and in a phone call at month 7.</AbstractText><AbstractText Label="SUMMARY OF RESULTS">Subjects were aged 64-83years (median 69.0years). Nineteen percent of subjects had serious or medically attended AEs up to Day 70 (primary endpoint), none of them causally linked to IXIARO. Solicited local AEs were reported by 33.5% (most common: local tenderness) and solicited systemic AEs by 27% (most common: headache) of subjects. The seroprotection rate was 65% with a geometric mean titre (GMT) of 37. Subjects with tick borne encephalitis (TBE) vaccinations in the past 5years (N=29) had a SCR of 90% and GMT of 65.</AbstractText><AbstractText Label="CONCLUSIONS">IXIARO is generally well tolerated in the elderly, and the safety profile is largely comparable with younger adults. SCR and GMT are lower compared to younger adults, but SCR is in the range reported in elderly for other vaccines e.g. against TBE, hepatitis-A virus (HAV)/hepatitis-B virus (HBV), influenza. The differences in SCR and GMT from younger to elderly adults were in the range of other vaccines. Duration of protection is uncertain in older persons, therefore a booster dose (third dose) should be considered before any further exposure to JE virus.</AbstractText><CopyrightInformation>Copyright © 2016. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cramer</LastName><ForeName>Jakob P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Bernhard Nocht Centre for Clinical Trials, Section Tropical Medicine/Infectious Diseases, I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany(1); Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dubischar</LastName><ForeName>Katrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Valneva Austria GmbH, Campus Vienna Biocenter 3, 1030 Vienna, Austria. Electronic address: Katrin.dubischar@valneva.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eder</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Valneva Austria GmbH, Campus Vienna Biocenter 3, 1030 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burchard</LastName><ForeName>Gerd D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Bernhard Nocht Centre for Clinical Trials, Section Tropical Medicine/Infectious Diseases, I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany(1); Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jelinek</LastName><ForeName>Tomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Berlin Center for Travel & Tropical Medicine, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jilma</LastName><ForeName>Bernd</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, Medical University of Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kollaritsch</LastName><ForeName>Herwig</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Specific Prophylaxis and Tropical Medicine, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reisinger</LastName><ForeName>Emil</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Tropical Medicine & Infectious Diseases, Rostock University Medical Center, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westritschnig</LastName><ForeName>Kerstin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Valneva Austria GmbH, Campus Vienna Biocenter 3, 1030 Vienna, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017429">Clinical Trial, Phase IV</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022321">Japanese Encephalitis Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001317" MajorTopicYN="N">Austria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004672" MajorTopicYN="N">Encephalitis, Japanese</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="Y">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022321" MajorTopicYN="N">Japanese Encephalitis Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069078" MajorTopicYN="N">Seroconversion</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Elderly</Keyword><Keyword MajorTopicYN="Y">Immunogenicity</Keyword><Keyword MajorTopicYN="Y">Japanese encephalitis</Keyword><Keyword MajorTopicYN="Y">Safety</Keyword><Keyword MajorTopicYN="Y">Vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>04</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>07</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>07</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>11</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27460550</ArticleId><ArticleId IdType="pii">S0264-410X(16)30612-0</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2016.07.029</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeAllemagneV3/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000082 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000082 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= GrippeAllemagneV3
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:27460550
|texte= Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:27460550" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV3
| This area was generated with Dilib version V0.6.35. |  |